leflunomide has been researched along with Proteinuria in 18 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 9.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
| " A previous study reported that leflunomide (LEF) with a corticosteroid was effective for adult patients with HSPN and nephrotic proteinuria." | 8.02 | Leflunomide therapy for IgA vasculitis with nephritis in children. ( Du, Y; Hou, L; Zhang, Z, 2021) |
| " This study aims to evaluate the effect of leflunomide on HSPN adults with nephrotic proteinuria." | 7.80 | Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria. ( Gao, Y; He, H; Liu, G; Liu, L; Zhang, Y; Zhang, Z, 2014) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 7.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Leflunomide (HWA 486, a novel isoxazol derivative), shown to have potent immunosuppressant and antiinflammatory effects, was evaluated for its inhibitory and therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against rat glomerular basement membrane." | 7.68 | Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Ogawa, T, 1990) |
| "A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 5.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
| "Leflunomide therapy significantly improved proteinuria (Plt;0." | 5.12 | [Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy]. ( Liu, ZR; Rong, L, 2007) |
| " A previous study reported that leflunomide (LEF) with a corticosteroid was effective for adult patients with HSPN and nephrotic proteinuria." | 4.02 | Leflunomide therapy for IgA vasculitis with nephritis in children. ( Du, Y; Hou, L; Zhang, Z, 2021) |
| " This study aims to evaluate the effect of leflunomide on HSPN adults with nephrotic proteinuria." | 3.80 | Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria. ( Gao, Y; He, H; Liu, G; Liu, L; Zhang, Y; Zhang, Z, 2014) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 3.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Leflunomide (HWA 486, a novel isoxazol derivative), shown to have potent immunosuppressant and antiinflammatory effects, was evaluated for its inhibitory and therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against rat glomerular basement membrane." | 3.68 | Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Ogawa, T, 1990) |
| "This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and kidney involvement." | 3.01 | Interventions for preventing and treating kidney disease in IgA vasculitis. ( Craig, JC; Hahn, D; Hodson, EM, 2023) |
| "The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions." | 2.80 | Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. ( Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015) |
| "In patients with IgA nephropathy and proteinuria > 1 g/day, steroid therapy given for generally two to four months with a tapering course probably prevents the progression to ESKD compared to placebo or standard care (8 studies; 741 participants: RR 0." | 2.66 | Immunosuppressive agents for treating IgA nephropathy. ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| "Primary IgA nephropathy (IgAN) and HSPN share common features; thus, the Oxford classification of IgAN might be useful in predicting the long-term outcomes of HSPN." | 1.48 | Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis. ( Ding, J; Li, Y; Su, B; Wang, F; Wang, S; Xiao, H; Xu, K; Zhang, L; Zhong, X, 2018) |
| "Biopsy-proved primary IgA nephropathy patients with an estimated glomerular filtration rate ≥ 30 ml/min/1." | 1.46 | Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. ( Cao, L; Che, X; Fang, W; Gu, L; Min, L; Mou, S; Ni, Z; Qian, J; Wang, L; Wang, Q; Yu, Z; Yuan, J; Zhang, M; Zhou, W; Zhu, M, 2017) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| " No serious adverse events were observed." | 1.39 | Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. ( Lu, W; Xie, L; Xue, W; Yang, S; Yin, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, L | 1 |
| Zhang, Z | 3 |
| Du, Y | 1 |
| Hahn, D | 1 |
| Hodson, EM | 1 |
| Craig, JC | 2 |
| Guo, Y | 2 |
| Wu, X | 1 |
| Liu, L | 3 |
| Zhang, H | 1 |
| Yang, L | 1 |
| Chen, W | 1 |
| Natale, P | 1 |
| Palmer, SC | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Vecchio, M | 1 |
| Samuels, JA | 1 |
| Molony, DA | 1 |
| Schena, FP | 1 |
| Strippoli, GF | 1 |
| Ni, Z | 3 |
| Yu, Z | 2 |
| Lu, F | 1 |
| Mei, C | 1 |
| Ding, X | 1 |
| Yuan, W | 1 |
| Zhang, W | 1 |
| Jiang, G | 2 |
| Sun, M | 2 |
| He, L | 1 |
| Deng, Y | 1 |
| Pang, H | 1 |
| Qian, J | 2 |
| Min, L | 1 |
| Wang, Q | 1 |
| Cao, L | 1 |
| Zhou, W | 1 |
| Yuan, J | 1 |
| Zhang, M | 2 |
| Che, X | 1 |
| Mou, S | 1 |
| Fang, W | 1 |
| Gu, L | 1 |
| Zhu, M | 1 |
| Wang, L | 3 |
| Xu, K | 1 |
| Zhang, L | 1 |
| Ding, J | 1 |
| Wang, S | 2 |
| Su, B | 1 |
| Xiao, H | 1 |
| Wang, F | 1 |
| Zhong, X | 2 |
| Li, Y | 1 |
| Chen, S | 1 |
| Yin, Q | 1 |
| Ren, S | 1 |
| Wang, W | 1 |
| Li, G | 1 |
| Qi, C | 1 |
| Zha, Y | 1 |
| Chen, J | 2 |
| Luo, P | 1 |
| Sun, Z | 1 |
| Wan, J | 1 |
| Xing, C | 1 |
| Chen, Q | 1 |
| Li, D | 1 |
| Guan, T | 1 |
| Yang, S | 1 |
| Xie, L | 1 |
| Xue, W | 1 |
| Yin, A | 1 |
| Lu, W | 1 |
| Zhang, Y | 1 |
| Gao, Y | 1 |
| Liu, G | 1 |
| He, H | 1 |
| Cheng, G | 1 |
| Liu, D | 1 |
| Margetts, P | 1 |
| Zhao, Z | 1 |
| Liu, Z | 2 |
| Tang, L | 1 |
| Fang, Y | 1 |
| Li, H | 1 |
| Chen, F | 1 |
| Liu, F | 1 |
| Hu, WX | 1 |
| Chen, YH | 1 |
| Bao, H | 1 |
| Liu, ZZ | 1 |
| Wang, SF | 1 |
| Zhang, HT | 1 |
| Liu, ZH | 1 |
| Wang, H | 1 |
| Sun, L | 1 |
| Tan, W | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Rong, L | 1 |
| Liu, ZR | 1 |
| Ogawa, T | 2 |
| Inazu, M | 2 |
| Gotoh, K | 2 |
| Inoue, T | 1 |
| Hayashi, S | 2 |
2 reviews available for leflunomide and Proteinuria
| Article | Year |
|---|---|
Interventions for preventing and treating kidney disease in IgA vasculitis.
Topics: Adult; Child; Fosinopril; Humans; IgA Vasculitis; Kidney Diseases; Leflunomide; Proteinuria; Tacroli | 2023 |
Immunosuppressive agents for treating IgA nephropathy.
Topics: Adult; Calcineurin Inhibitors; Cause of Death; Child; Confidence Intervals; Creatinine; Drug Adminis | 2020 |
5 trials available for leflunomide and Proteinuria
| Article | Year |
|---|---|
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Topics: Adult; Autoantibodies; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonep | 2020 |
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Topics: Adult; China; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulone | 2021 |
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Topics: Adult; Antibodies, Antinuclear; China; Complement C3; Cyclophosphamide; DNA; Drug Therapy, Combinati | 2019 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease | 2015 |
[Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy].
Topics: Adult; Drug Resistance; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Hormones; Humans | 2007 |
11 other studies available for leflunomide and Proteinuria
| Article | Year |
|---|---|
Leflunomide therapy for IgA vasculitis with nephritis in children.
Topics: Adult; Child; Humans; IgA Vasculitis; Immunoglobulin A; Leflunomide; Nephritis; Proteinuria | 2021 |
Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Biomarkers; Blood Pressure; Disease Progression; Drug Therapy, Combi | 2017 |
Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
Topics: Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Atrophy; Biopsy; Child; Child, Pr | 2018 |
A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
Topics: Adrenal Cortex Hormones; Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2018 |
Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biopsy; China; Drug Therapy, Combination; Female; Glo | 2013 |
Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria.
Topics: Adrenal Cortex Hormones; Adult; Aged; Female; Humans; IgA Vasculitis; Isoxazoles; Kidney; Leflunomid | 2014 |
Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases.
Topics: Adolescent; Anemia; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Child; Child, | 2015 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |
Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Azathioprine; Basement | 1991 |
Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basement Membrane; Cell Division; Complement C3; F | 1990 |